These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9332314)

  • 1. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients.
    Di Gregorio F; Romeo MA; Pizzarelli G; Aiello G; Russo G
    Br J Haematol; 1997 Sep; 98(3):601-2. PubMed ID: 9332314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
    Yarali N; Fişgin T; Duru F; Kara A; Ecin N; Fitoz S; Erden I
    J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new method of administration of the iron chelating agent deferoxamine.
    Borgna-Pignatti C; Cohen A
    J Pediatr; 1997 Jan; 130(1):86-8. PubMed ID: 9003855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous desferrioxamine infusion by an infusor in thalassaemia major.
    Canatan D; Temimhan N; Dinçer N; Ozsancak A; Oğuz N; Temimhan M
    Acta Paediatr; 1999 May; 88(5):550-2. PubMed ID: 10426179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience.
    Songdej D; Sirachainan N; Wongwerawattanakoon P; Sasanakul W; Kadegasem P; Sungkarat W; Chuansumrit A
    Acta Haematol; 2015; 133(2):226-36. PubMed ID: 25376266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME; Matthews RN; Alison JF; Menahem S; Mitvalsky J; Byrt E; Harper RW
    Aust N Z J Med; 1993 Dec; 23(6):656-61. PubMed ID: 8141693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of iron excretion in relation to haemoglobin level and iron load in 8 haematological patients following the administration of subcutaneous deferrioxamine.
    Di Palma A; Moratelli S; Tolomelli P; Giuberti M; Tenan R; Fagioli F; Landi L; Toffoli C; Atti G; Vullo C
    Eur J Haematol; 1994 Oct; 53(4):197-200. PubMed ID: 7957802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy.
    Pearson HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):160-2. PubMed ID: 17356394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
    Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.
    Araujo A; Kosaryan M; MacDowell A; Wickens D; Puri S; Wonke B; Hoffbrand AV
    Br J Haematol; 1996 Jun; 93(4):835-7. PubMed ID: 8703813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.